백내장 수술 후 생긴 낭포황반부종에서의 유리체강내 트리암시놀론 주입술 일차치료 효과
Effect of Intravitreal Injection as a Primary Treatment in Cystoid Macular Edema after Cataract Surgery
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
목적: 백내장 수술 뒤의 낭포황반부종을 진단받은 환자들을 대상으로 유리체강내 트리암시놀론 주입술을 시행한 후 임상양상을 보고자 하였다. 대상과 방법: 2006년 3월부터 2008년 3월까지 백내장 수술 후 생긴 낭포황반부종을 진단받은 환자들을 대상으로 일차치료로 유리체강내 트리암시놀론 주입술을 시행하였다. 최대교정시력과 중심황반두께를 측정하고, 주사 후 부작용, 낭포황반부종의 호전과 재발여부를 확인하였다. 결과: 총 12안으로, 평균나이는 67.3세, 백내장 수술 후 발병까지의 평균 기간은 7.6주였다. 유리체강내 트리암시놀론 주입술을 시행하였으며 시술 후 평균 6.7개월간 경과 관찰하였다. 최대교정시력(logMAR)은 평균 0.29±0.12에서 0.11±0.09로 향상되었으며(p=0.000), 중심황반두께는 평균 390.58±94.98 μm에서 165.17±39.95 μm로 감소하였다(p=0.001). 시술 후 합병증은 없었으며 12안에서 한 달 뒤 시력과 부종의 호전을 보였다. 결론: 백내장 수술 후 낭포황반부종의 일차 치료방법으로 유리체강내 주입술을 시행한 결과 12안에서 빠른 시간 내에 시력과 황반두께의 회복이 있음을 확인할 수 있었다.
Abstract
Purpose: To report the clinical manifestations of intravitreal triamcinolone injection as a primary treatment method for patients with cystoid macular edema after cataract surgery. Methods: The present retrospective study was comprised of patients diagnosed with cystoid macular edema after cataract surgery performed between March 2006 and March 2008. To treat the edema, intravitreal triamcinolone injection was administered. Best corrected visual acuity (BCVA) and central macular thickness were measured, and complications as well as efficacy of the treatment were evaluated. Results: Twelve eyes were selected for the present study with a mean patient age of 67.3 years. The average period between cataract surgery and diagnosis of cystoid macular edema was 7.6 weeks. All 12 eyes received an intravitreal triamcinolone injection, and the patients were followed up for an average of 6.7 months. BCVA (log MAR) was changed from 0.29±0.12 to 0.11±0.09, showing statistically significant improvement (p = 0.000). The OCT showed that the average CMT was statistically decreased from 390.58±94.98 μm to 165.17±39.95 μm (p = 0.001). No complications were reported after the procedure, and vision and edema improved after one month in all 12 eyes. Conclusions: After performing intravitreal triamcinolone injection as a primary treatment method for cystoid macular edema which developed after cataract surgery, rapid recovery and improvement of vision and macular thickness were confirmed in all 12 eyes.
참고문헌 (19)
- Gass JD, "Cystoid macular edema and papilledema following cataract extraction. A fluorescein funduscopic and angiographic study", Arch Ophthalmol, 76, pp.646~661 (1966)
- Jaffe NS, "Cataract Surgery and Its Complications, 4th ed", pp.426~441 (1984), Mosby
- Kim JC, "Cystoid macular edema in pseudophakia", J Korean Ophthalmol Soc, 31, pp.1148~1151 (1990)
- Drolsum L, "Causes of decreased visual acuity after cataract extraction", J Cataract Refract Surg, 21, pp.59~63 (1995)
- Flach AJ., "The incidence, pathogenesis, and treatment of cystoid macular edema following cataract surgery", Trans Am Ophthalmol Soc, 96, pp.557~634 (1998)
- Levin DS, "Update on pseudophakic cystoid macular edema treatment options", Ophthalmol Clin North Am, 15, pp.467~472 (2002)
- Stark WJ Jr, "Cystoid macular edema in pseudophakia", Surv Ophthalmol, 28(Suppl), pp.442~451 (1984)
- Arevalo JF, "Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group Results", Ophthalmology, 116, pp.1481~1487 (2009)
- Flach AJ, "The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery", Trans Am Ophthalmol Soc, 96, pp.557~634 (1998)
- Miyake K, "Prostaglandins and cystoid macular edema", Surv Ophthalmol, 47(Suppl 1), pp.203~218 (2002)
- Flach AJ, "Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema", Am J Ophthalmol, 103, pp.479~486 (1987)
- Flach AJ, "Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine", Am J Ophthalmol, 112, pp.514~519 (1991)
- Shulman S, "Prognostic factors for visual acuity improvement after intravitreal triamcinolone injection", Eye (Lond), 21, pp.1067~1070 (2007)
- Koutsandrea C, "Intraocular triancinolone acetonide for pseudophakic cystoids macular edema: optical coherence tomography and multifocal electroretinography study", Retina, 27, pp.159~164 (2007)
- Karacorlu M, "Intravitreal triamcinolone acetonide for the treatment of chronic pseudophakic cystoid macular oedema", Acta Ophthalmol Scand, 81, pp.648~652 (2003)
- Negi AK, "Intravitreal triamcinolone improves vision in eyes with chronic diabetic macular oedema refractory to laser photocoagulation", Eye (Lond), 19, pp.747~751 (2005)
- Noma H, "Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion", Graefes Arch Clin Exp Ophthalmol, 244, pp.309~315 (2006)
- Mason JO 3rd, "Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema", Retina, 26, pp.356~357 (2006)
- Barone A, "Successful treatment of pseudophakic cystoid macular edema with intravitreal bevacizumab", J Cataract Refract Surg, 34, pp.1210~1212 (2008)